Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness of Subcutaneous Anifrolumab in Systemic Lupus Erythematodes - A Non-interventional, Prospective, Multicenter Study on Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care

NCT07424261 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07424261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07424261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness of Subcutaneous Anifrolumab in Systemic Lupus Erythematodes - A Non-interventional, Prospective, Multicenter Study on Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
March 19, 2026
Completion date
August 31, 2029
Enrollment
125 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

lupus erythematosus, systemic